DEVELOPING EUROPE & CIS
The main revenue contributor to our Developing Europe & CIS business is the Thrombosis Brands, followed by Regional Brands which are OTC and prescription.
Key Countries
The Czech Republic
Poland
Romania
Russia
Slovakia

- The Developing Europe & CIS Injectable thrombosis market was valued at EUR318 million as at March 2020.
Source: IQVIA – March 2020
STATISTICS
Number of products launched:
Nil
(2019: Nil)
Average staff turnover:
20%
(2019: 18%)
Number of product recalls:
Nil
(2019: Nil)
Number of work-related fatalities:
Nil
(2019: Nil)
Number of permanent employees | ||
273June 2020 |
264June 2019 |
Revenue | 2020 R’million |
2019 (CER) R’million |
Change % |
||||
---|---|---|---|---|---|---|---|
Regional Brands | 435 | 393 | 11 | ||||
Sterile Focus Brands | 2 116 | 2 289 | (8) | ||||
Anaesthetics Brands | 174 | 299 | (42) | ||||
Thrombosis Brands | 1 942 | 1 990 | (2) | ||||
Total | 2 551 | 2 682 | (5) |
Note: Commercial Pharmaceuticals revenue by customer geography.